Genetic markers indicate that 1,25-dihydroxyvitamin d treatment may not protect against hepatocellular carcinoma
dc.authorid | 0000-0003-3771-3277 | en_US |
dc.contributor.author | Öner, Çağrı | |
dc.contributor.author | Çolak, Ertuğrul | |
dc.date.accessioned | 2024-07-12T21:03:32Z | |
dc.date.available | 2024-07-12T21:03:32Z | |
dc.date.issued | 2021 | en_US |
dc.department | Fakülteler, Tıp Fakültesi | en_US |
dc.description.abstract | Objectives: The impact of 1,25-dihydroxyvitamin D on hepatocellular carcinoma (HCC) cells is a complicated area. In this study, we aimed to clarify the effect of 1,25-dihydroxyvitamin D on HCC cells according to genetic markers. Methods: The optimal concentration of 1,25-dihydroxyvitamin D is treated to HepG2 cells (250 nM at the 48th hour). From treated HepG2 cells, total Ribonucleic Acid (RNA) was isolated, and Ki-67, MMP-2, MMP-9, HIF-1?, hTERT, and piR823 gene expressions were determined by SYBR Green-based real-time polymerase chain reaction. Results: : Increased expressions of Ki-67, hTERT, and piR-823 were determined compared with the control group at the 48th hour after treatment (p<0.001), while decreased gene expressions of MMP-2, MMP-9, and HIF-1? were observed compared with the control group (p<0.001). Conclusion: Currently, there are several different opinions about the usage of vitamin D, especially in HCC. In addition to researchers who argue that vitamin D has anticarcinogenic and protective properties, an increasing number of researchers argue that tumor cells can become aggressive after HCC occurs. According to our results, it was determined that vitamin D causes HepG2 HCC cells to become aggressive in terms of gene expression in the parameters used as a marker for proliferation, adhesion, and differentiation. | en_US |
dc.identifier.citation | Öner, Ç. ve Çolak, E. (2021). Genetic markers indicate that 1,25-dihydroxyvitamin d treatment may not protect against hepatocellular carcinoma. Eurasian Journal of Medicine and Oncology, Kare Publishing. 5(2), s. 117-122. | en_US |
dc.identifier.doi | 10.14744/ejmo.2021.65874 | |
dc.identifier.endpage | 122 | en_US |
dc.identifier.issn | 2587-196X | |
dc.identifier.issue | 2 | en_US |
dc.identifier.scopus | 2-s2.0-85117246800 | en_US |
dc.identifier.scopusquality | Q3 | en_US |
dc.identifier.startpage | 117 | en_US |
dc.identifier.trdizinid | 488004 | en_US |
dc.identifier.uri | https://www.ejmo.org/10.14744/ejmo.2021.65874/ | |
dc.identifier.uri | https://doi.prg/10.14744/ejmo.2021.65874 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12415/3678 | |
dc.identifier.volume | 5 | en_US |
dc.identifier.wos | WOS:000672748800004 | en_US |
dc.identifier.wosquality | N/A | en_US |
dc.indekslendigikaynak | Web of Science | |
dc.indekslendigikaynak | Scopus | |
dc.indekslendigikaynak | TR-Dizin | |
dc.institutionauthor | Öner, Çağrı | |
dc.language.iso | en | en_US |
dc.publisher | Kare Publishing | en_US |
dc.relation.ispartof | Eurasian Journal of Medicine and Oncology | en_US |
dc.relation.publicationcategory | Ulusal Hakemli Dergide Makale - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.snmz | KY00828 | |
dc.subject | 1.25-Dihydroxyvitamin D | en_US |
dc.subject | hepatocellular carcinoma | en_US |
dc.subject | motility | en_US |
dc.subject | PIWI interacting RNA | en_US |
dc.subject | proliferation | en_US |
dc.title | Genetic markers indicate that 1,25-dihydroxyvitamin d treatment may not protect against hepatocellular carcinoma | en_US |
dc.type | Article | |
dspace.entity.type | Publication |